Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders

Publication date

2021-08

Authors

Sofias, Alexandros MariosISNI 0000000527553331
De Lorenzi, Federica
Peña, Quim
Azadkhah Shalmani, Armin
Vucur, Mihael
Wang, Jiong-Wei
Kiessling, Fabian
Shi, YangISNI 0000000527247967
Consolino, Lorena
Storm, GertISNI 0000000042534976

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

taverne

Abstract

Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies.

Keywords

Fibrosis, Drug targeting, Nanomedicine, Imaging, Atherosclerosis, Cardiovascular disease, Cancer, Diabetes, Liver, Viral infection, Taverne, SDG 3 - Good Health and Well-being

Citation

Sofias, A M, De Lorenzi, F, Peña, Q, Azadkhah Shalmani, A, Vucur, M, Wang, J-W, Kiessling, F, Shi, Y, Consolino, L, Storm, G & Lammers, T 2021, 'Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders', Advanced Drug Delivery Reviews, vol. 175, 113831, pp. 1-36. https://doi.org/10.1016/j.addr.2021.113831